Complete Remission News Today

Iomab-B significantly improved outcomes in TP53 positive patients with a median overall survival of 5.49 months versus 1.66 months in those not receiving Iomab-B (hazard ratio = 0.23, p-value=0.0002) in

House Majority Leader Steve Scalise (R-La.) is in “complete remission” after treatment for blood cancer and will return to Washington for votes next week after an extended absence, his office announced Thursday. “Leader Scalise has successfully completed his autologous stem cell treatment and has been medically cleared to resume travel,” Scalise’s office said in a…

NEW YORK - Actinium Pharmaceuticals, Inc. , a leader in the development of targeted radiotherapies, today highlighted four presentations at the 65th Annual American Society of Hematology Annual...

<p>A study led by researchers at <a href="https://umiamihealth.org/en/sylvester-comprehensive-cancer-center"><strong>Sylvester Comprehensive Cancer Center</strong></a> suggests that CAR-T immunotherapy remains a viable option for patients who have lymphoma that goes into remission before the cell therapy begins. Video available.</p>

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today...

Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) unveiled promising results from its BEXMAB trial at a leading medical conference, showcasing a new...

Actinium Pharmaceuticals, Inc. reported results from the Phase 3 SIERRA trial of Iomab-B. The company said Iomab-B achieved the primary endpoint in the SIERRA trial of durable Complete Remission or dCR of at least 6 months with high statistical significance, with 22% of patients randomized to the Iomab-B arm achieving dCR and 0% of patients in the control arm achieving dCR, irrespective of TP53 mutational status.

Experts recently debated whether additional intensive therapy can improve posttransplant outcomes for patients with acute myeloid leukemia who have residual disease after induction therapy.

/PRNewswire/ -- Guangzhou Gloria Biosciences ("GloriaBio"), a commercial stage biopharmaceutical company focusing on the discovery, development and...

/PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today...